Oral

Lumos Pharma Reports Full Year 2021 Financial Results and Announces Plan to Perform Interim Analyses of OraGrowtH Trials

Retrieved on: 
Thursday, March 10, 2022
Therapy, Particle-size distribution, Degenerative disease, Transgender hormone therapy, UCB, Depreciation, Disease, Safety, Orphan, Drug development, Company, LUMO, FDA, Data, Optimism, GLOBE, Patient, Uncertainty, SEC, CEO, NASDAQ, Clinical trial, LUM, Private Securities Litigation Reform Act, Oral, PD, Risk, PEM, Growth hormone, Webcast, Research, NEA, New Enterprise Associates, Interim analysis, Pandemic, Pharmaceutical industry, Animal, Risk management, Public relations, Lumos, EU

We are excited to announce that we plan to conduct interim analyses on two of our OraGrowtH Trials evaluating orally administered LUM-201 in PGHD, commented Rick Hawkins, Chairman and CEO of Lumos Pharma.

Key Points: 
  • We are excited to announce that we plan to conduct interim analyses on two of our OraGrowtH Trials evaluating orally administered LUM-201 in PGHD, commented Rick Hawkins, Chairman and CEO of Lumos Pharma.
  • No patients had been randomized to treatment in the clinical trial at any of our nine sites in Ukraine and Russia.
  • Financial Results for the Year Ended December 31, 2021
    Cash Position Lumos Pharma ended the year on December 31, 2021, with cash and cash equivalents totaling $94.8 million compared to $98.7million on December 31, 2020.
  • Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases.

C4 Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 2022 

Retrieved on: 
Tuesday, March 8, 2022
Multiple myeloma, FIH, Risk, U.S. Securities and Exchange Commission, Investor, IKZF1, Private Securities Litigation Reform Act, Medicine, Oncology, B-cell lymphoma, Discovery, Conference call, Target protein, Therapy, Novel, Disease, BRAF, Poster, American Association for Cancer Research, Company, Emory University, BRD9, Result, Initial, Chemistry, GLOBE, Patient, Emory University School of Medicine, Drug resistance, Webcast, Oral, Research, Annual report, NHL 21, Conference, IKZF3, Lymphoma, Treatment, Security (finance), CCCC, Association, Proteomics, FACP, Hematology, AACR, Clinical data repository, MCL, Winship Cancer Institute, PTCL, Ongo, Mantle cell lymphoma, Controlled Impact Demonstration, American Association, Pharmaceutical industry, C4

WATERTOWN, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced that the Company will present a poster and three oral presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022, taking place between April 8-13, 2022 in New Orleans, Louisiana and virtually.

Key Points: 
  • The webcast can be accessed under Events & Presentations in the Investors section of the companys website at www.c4therapeutics.com .
  • A replay of the webcast will be available on C4Ts website for 30 days following the event.
  • C4T is advancing multiple targeted oncology programs to the clinic and expanding its research platform to deliver the next wave of medicines for difficult-to-treat diseases.
  • This press release contains forward-looking statements of C4 Therapeutics, Inc. within the meaning of the Private Securities Litigation Reform Act of 1995.

Cara Therapeutics Announces Oral KORSUVA™ (difelikefalin) Data Selected for Late-Breaking Presentation at 2022 American Academy of Dermatology Annual Meeting

Retrieved on: 
Tuesday, March 8, 2022
Nasdaq, Atopic dermatitis, Humanitas University, Primary biliary cholangitis, Twitter, American Academy, AAD, Itch, Company, Oral, Department, Webcast, FDA, Instagram, MTR, Mount Sinai, Q&A, Icahn School of Medicine at Mount Sinai, KARE, GLOBE, News, Patient, American Academy of Dermatology, Chronic kidney disease, Therapy, Biomedical sciences, LinkedIn, Pharmaceutical industry, Dietary supplement, MD, Medicine

STAMFORD, Conn., March 08, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced biomarker data from the KARE Phase 2 clinical trial evaluating Oral KORSUVA™ (difelikefalin) for the treatment of moderate-to-severe pruritus in atopic dermatitis patients will be presented in a late-breaking oral presentation at the 2022 American Academy of Dermatology (AAD) Annual Meeting, to be held March 25-29, 2022, in Boston, MA.

Key Points: 
  • ET on March 11, 2022, which will focus on the initiation of Oral KORSUVA (difelikefalin) Phase 3 programs for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis, respectively.
  • Cara Therapeutics is an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus.
  • The Companys novel KORSUVA (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis.
  • Phase 2 trials of Oral KORSUVA (difelikefalin) are ongoing in primary biliary cholangitis and notalgia paresthetica patients with moderate-to-severe pruritus.

Alzheon to Present ALZ-801 (Valiltramiprosate) Phase 3 Program Update and Industry-Leading Disease Modifying Effects from Phase 2 Trial in Patients with Early Alzheimer’s Disease at AD/PD and NDDS Scientific Conferences

Retrieved on: 
Tuesday, March 8, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Risk, NDA, Diagnosis, Neurotoxicity, Ageing, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Oral, Reverse-path forwarding, Plasma, Biomarker, Science, AD, Food, Alzheimer's disease, Doctor of Philosophy, Safety, Lists of diseases, Neurodegeneration, Cerebral edema, Program, New Drug Application, Precision medicine, Plaque, Fast Track, Disease, Conference, CEO, Maintenance, National Institute, National Institute on Aging, Technology, Brain, International Conference on Emerging Infectious Diseases, MD, Pathology, Pharmaceutical industry, Medical imaging, Alzheon, APOE4

This oral presentation will be included in the Scientific Symposium: APOE Mechanisms and Treatment Strategies and can be accessed through the conference virtual portal or directly onsite.

Key Points: 
  • This oral presentation will be included in the Scientific Symposium: APOE Mechanisms and Treatment Strategies and can be accessed through the conference virtual portal or directly onsite.
  • At the NDDS conference, Dr. John Hey, Chief Scientific Officer of Alzheon and Alzheon CEO, Dr. Martin Tolar will give oral presentations on Tuesday, March 29, 2022, at 12:30 p.m.
  • This is a double-blind, randomized trial comparing one dose of oral ALZ-801 to placebo treatment over 78 weeks.
  • Our lead Alzheimers clinical candidate, ALZ-801 , is an oral agent in Phase 3 development as a potentially disease modifying treatment for AD.

Worldwide Oral Cancer Treatment Industry to 2030 - Featuring Cipla, Sanofi and Teva Pharmaceuticals Industries Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 3, 2022
Pharmaceutical, Health, Oncology, Oral, Oral cancer, Recurrence, Death, Immunotherapy, Treatment, Woman, Prevalence, Risk, Mouth, Awareness, Human papillomavirus infection, Growth, Head, Man, Disease, Profile, Smokeless tobacco, National Cancer Institute, Exocrine gland, Squamous cell carcinoma, CAGR, Tongue, Malignancy, Oropharyngeal cancer, National, Neoplasm, Dentistry, Birth control

The global oral cancer treatment market was valued at $ 1,710.53 million 2020, and is projected to reach $ 2,729.72 Million by 2030 registering a CAGR of 4.80% from 2021 to 2030.

Key Points: 
  • The global oral cancer treatment market was valued at $ 1,710.53 million 2020, and is projected to reach $ 2,729.72 Million by 2030 registering a CAGR of 4.80% from 2021 to 2030.
  • Oral cancer is a type of head and neck cancer that manifests itself in the mouth as a tumor.
  • Furthermore, according to the Oral Cancer Foundation, every year around 53,000 new oral cancer cases are diagnosed and more than 9,750 people succumb to the disease in the U.S.
  • The oral cancer treatment market is segmented on the basis of treatment, age group, end user, and region.

TFF Pharmaceuticals and Catalent Announce New Inhalation Dry Powder Development and Manufacturing Agreement

Retrieved on: 
Tuesday, March 1, 2022
GLOBE, Risk, Absorption, Pharmacokinetics, NASDAQ, TFF, Annual report, Therapy, Industry, Company, CGMP, Inhalation, Adoption, Acquisition, Spray drying, FDA, Patient, Technology, Solubility, Catalent, Oral, Freezing, SEC, Acorda Therapeutics, Pharmaceutical industry, Fine chemical

Collaboration focused on development of dry powder formulations of therapies, specifically biotherapeutics, for inhaled delivery

Key Points: 
  • Collaboration focused on development of dry powder formulations of therapies, specifically biotherapeutics, for inhaled delivery
    AUSTIN, Texas and SOMERSET, N.J., March 01, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc.(NASDAQ: TFFP) and Catalent today announced their collaboration agreement focused on the generation, testing and manufacture of dry powder formulations for a range of biotherapeutics through the application of TFF Pharmaceuticals patented Thin Film Freezing (TFF) technology.
  • Under the agreement, Catalent will provide its scale-up expertise and manufacturing capabilities to TFF Pharmaceuticals as its preferred development and manufacturing partner, and Catalent will be able to offer its customers access to the innovative TFF technology, which has the potential to increase the adoption of the pulmonary route for the systemic delivery of biotherapeutics.
  • We are therefore delighted to significantly expand our collaboration with the Catalent team, stated Glenn Mattes, Chief Executive Officer of TFF Pharmaceuticals.
  • Jonathan Arnold, President, Oral and Specialty Delivery at Catalent added, Catalent is pleased to leverage its extensive expertise in the development and CGMP manufacture of dry powders in order to potentially bring TFF Pharmaceuticals unique and differentiated technology to scale.

Dermatology Residents Recognized With Resident of Distinction Award™ at Maui Derm 2022

Retrieved on: 
Monday, February 28, 2022
GLOBE, Distinction, Overalls, Saint Louis University, Organic acid, University, Use, Dermatology, LLC, Treatment, Resident, Oral, Mentorship, Research, Health insurance, New York University, MD

WAILEA, Hawaii, Feb. 28, 2022 (GLOBE NEWSWIRE) -- DermMentors announced as part of the 11th Annual dermMentors Resident of Distinction Award the five resident awardees and overall grand prize recipient for 2022.

Key Points: 
  • WAILEA, Hawaii, Feb. 28, 2022 (GLOBE NEWSWIRE) -- DermMentors announced as part of the 11th Annual dermMentors Resident of Distinction Award the five resident awardees and overall grand prize recipient for 2022.
  • Beiersdorf Inc. sponsored the five top dermatology residents to attend the 2022 Maui Derm for Dermatologists conference, held in Wailea Beach, Maui, Hawaii, from Jan. 24-28, 2022.
  • The Residents presented their research during Maui Derm "Talk Story" sessions on Jan. 24-26.
  • Now in its 11th year, the dermMentors Resident of Distinction Award recognizes top residents in dermatology for their standout research and dedication to their field, while providing them with insights from respected thought leaders, and facilitating and fostering relationships between residents and mentors in dermatology.

Global Multiple Sclerosis Market Segmentation 2021-2026, By Drug Class, Route of Administration and Distribution Channel - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 24, 2022
Health, Pharmaceutical, Online, Government, Growth, GlaxoSmithKline, Pfizer, Multiple sclerosis, Biogen, Market share, COVID-19, Industry, MS, Person, Bristol Myers Squibb, Route of administration, Administration, USD, Interferon, Hospital pharmacy, Drug class, Traction, Patient, Quality of life, Oral, Novartis, Radiology, Distribution, Immune disorder, Pipeline, Online pharmacy, Pharmaceutical industry, Drug, Frankincense, Pet, Global

The Global Multiple Sclerosis Market was estimated at USD 26.01 Billion in the year 2020.

Key Points: 
  • The Global Multiple Sclerosis Market was estimated at USD 26.01 Billion in the year 2020.
  • The introduction of disease-modifying drugs as a treatment option is a key factor that drives the growth of the global multiple sclerosis market.
  • Moreover, the growth of the global multiple sclerosis market is driven by shift in preference toward oral drugs.
  • Global Multiple Sclerosis Market Segmentation - By Drug Class, By route of Administration, By Distribution Channel
    North America Multiple Sclerosis Market: An Analysis (2016-2026)
    Asia Pacific Multiple Sclerosis Market: An Analysis (2016-2026)

Henry Schein to Showcase a Wide Portfolio of Products, Services, and Solutions During the Chicago Midwinter Dental Meeting

Retrieved on: 
Wednesday, February 23, 2022
Hospitals, Health, Dental, Practice Management, Medical Supplies, Emerald, ASDA, DSO, Septodont, Government, Jarvis, Method, Schick, Studio, American Student Dental Association, Intraoral camera, S&P, Collection, Company, CBCT, DVD Studio Pro, Practice management, CAD/CAM, Private, CMW, Clear aligners, Leadership, Supply chain, Procurement, Nasdaq, Marketing, Oral, Solution, Communication, Program, IMac, Risk management, Management, Transcendental Meditation movement, KAVO, Dental, Technology

Henry Schein, Inc. (Nasdaq: HSIC) announced today a wide-ranging lineup of products, services, and solutions to advance practice performance at the 2022 Chicago Midwinter Dental Meeting (CMW), taking place February 24-26, 2022.

Key Points: 
  • Henry Schein, Inc. (Nasdaq: HSIC) announced today a wide-ranging lineup of products, services, and solutions to advance practice performance at the 2022 Chicago Midwinter Dental Meeting (CMW), taking place February 24-26, 2022.
  • The Henry Schein booth will also feature new digital equipment solutions, including the Medit i700 scanner, which offers a more comfortable scanning experience.
  • The Chicago Midwinter Dental Meeting is an important meeting for us to connect with our customers and the dental community in a meaningful way, said AJ Caffentzis, President, U.S.
  • Throughout the meeting, Henry Schein will demonstrate the latest core and digital equipment solutions, including CBCT and CAD/CAM, intraoral scanners, and 3D printers.

Henry Schein Presents “Optimism and Opportunities in Oral Health” Virtual Program

Retrieved on: 
Tuesday, February 22, 2022
Health, Dental, Practice Management, Medical Supplies, ASDA, Division, Government, University of Minnesota School of Dentistry, Chicago, Progress, American Student Dental Association, Henry Schein, Hospital, University, S&P, New Perspective on Paul, Industry, Company, Pediatric dentistry, Future, Oral and maxillofacial surgery, Multimedia, Oral medicine, American Association of Oral and Maxillofacial Surgeons, Supply chain, Nasdaq, Pacific Northwest, Oral, Solution, Program, CEO, Management, Dentistry, New, Technology

Henry Schein, Inc. (Nasdaq: HSIC) announced today the launch of its virtual program, Optimism and Opportunities in Oral Health.

Key Points: 
  • Henry Schein, Inc. (Nasdaq: HSIC) announced today the launch of its virtual program, Optimism and Opportunities in Oral Health.
  • This virtual program exemplifies our commitment to providing unique perspectives as we collectively work to advance dentistry.
  • To watch Optimism and Opportunities in Oral Health on demand, please click here .
  • Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for health care professionals powered by a network of people and technology.